244 related articles for article (PubMed ID: 9679910)
1. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
3. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
7. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
8. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
9. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
10. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
13. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
14. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
15. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
[TBL] [Abstract][Full Text] [Related]
16. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
17. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
18. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
20. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
Lopez S; Simon JM; Mazeron JJ
Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]